Clinical Trial Update: Influence of Cytochrome CYP3A4-induction by St. John's Wort on the Steady State Pharmacokinetics of Ambrisentan

View source ↗

Summary

A clinical trial update reported results on how CYP3A4 induction by St. John's Wort alters the steady-state pharmacokinetics of ambrisentan, highlighting potent…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• LETAIRIS (ambrisentan)
• St. John's Wort (Hypericum perforatum)

Snippet

Sponsor: Gerd Mikus | Conditions: Drug Interactions | Status: COMPLETED | Results posted: 2015-06-02